Crohn’s disease

Genetic Risk of Inflammatory Bowel Disease Linked to Disease Severity

By MedXY 05/01/2026

A Danish nationwide study reveals higher genetic risk scores for IBD predict more severe disease courses, including increased surgery rates, stronger medication needs, and worse inflammatory markers in both Crohn's and ulcerative colitis patients.

Gastroenterology Internal Medicine news

Reduced Intestinal Epithelial GPX4 Expression Predicts Postoperative Crohn’s Disease Recurrence and Offers a Novel Therapeutic Target

By MedXY 03/22/2026

A breakthrough study identifies epithelial Glutathione peroxidase 4 (GPX4) deficiency as a potent predictor of Crohn's disease recurrence after surgery. The research links this biomarker to endoplasmic reticulum stress and highlights selenium supplementation as a potential druggable strategy to improve patient outcomes.

Gastroenterology news

Beyond Clinical Remission: Why Diet and Gut Signatures Remain Perturbed in Crohn’s Disease

By MedXY 03/10/2026

A multi-omic study reveals that despite effective immune suppression, Crohn's disease patients in remission exhibit persistent dietary, microbial, and metabolic abnormalities. This research highlights the critical role of ultraprocessed foods and epithelial stress in preventing total disease clearance.

Gastroenterology General Surgery news

Stem Cell Therapy for Complex Perianal Fistulas: Why the ADMIRE CD II Trial Missed Its Mark

By MedXY 03/06/2026

The ADMIRE CD II Phase 3 trial failed to show a significant benefit of darvadstrocel over placebo for complex perianal fistulas in Crohn's disease, primarily due to an unexpectedly high remission rate in the placebo-controlled surgical arm.

Gastroenterology news Pediatrics

Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease

By MedXY 02/24/2026

The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-term pharmacological interventions.

Gastroenterology Internal Medicine news

Is 2 Liters of PEG Necessary? Simplified Water Prep Proves Effective for Crohn’s Capsule Endoscopy

By MedXY 01/20/2026

A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving patient acceptability and comfort.

Gastroenterology news

Vedolizumab Is Safer and More Effective When Used Early in Crohn’s Disease: Results from the Phase 4 LOVE‑CD Cohort

By MedXY 11/09/2025

The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.

Gastroenterology news Pathology & Lab Medicine

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

By MedXY 11/09/2025

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.

Gastroenterology news

EASE‑CD: A Validated, Responsive Endoscopic Ulcer Activity Score That Advances Outcome Measurement in Crohn’s Disease

By MedXY 11/09/2025

A new continuous index—EASE‑CD—focuses on ulcer presence, size, depth and proportion of ulcerated surface; it is reliable, responsive, and externally validated across two RCT datasets, offering a practical endoscopic endpoint for trials and potentially clinical care.

Gastroenterology news Specialties

Unraveling the Paradox: Why Smoking Benefits Ulcerative Colitis but Worsens Crohn’s Disease

By MedXY 09/04/2025

Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.

Clinical Updates Gastroenterology Specialties

Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials

By MedXY 08/02/2025

Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.

Clinical Updates Gastroenterology news Specialties

EASE-CD: A Validated Endoscopic Ulcer Activity Score for Crohn’s Disease—Clinical Utility and Evidence from Randomized Trials

By MedXY 08/02/2025

The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn's disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.